The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments

Cesare Gridelli, Paolo Maione, Antonio Rossi, Filippo De Marinis

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease, and despite the improvement in efficacy and safety outcomes with platinum-based chemotherapy, this standard cytotoxic approach has reached a therapeutic plateau, with the prognosis for this clinical condition remaining poor. Advances in the knowledge of tumor biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. Bevacizumab, an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, is the antiangiogenic agent at the most advanced stage of development in the treatment of solid tumors and also in NSCLC treatment. Bevacizumab, combined with platinum-based chemotherapy, has been demonstrated to improve efficacy outcomes over chemotherapy alone in the treatment of nonsquamous advanced NSCLC in two phase III randomized trials. These represent the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment will include the combination of this agent with other targeted therapies in advanced disease (especially with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor) and the integration of this agent into combined modality approaches for the treatment of early-stage and locally advanced disease.

Original languageEnglish
Pages (from-to)1183-1193
Number of pages11
JournalThe oncologist
Volume12
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Drug Therapy
Platinum
Bevacizumab
Angiogenesis Inhibitors
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Neoplasms
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Monoclonal Antibodies
Safety

Keywords

  • Angiogenesis
  • Bevacizumab
  • NSCLC
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

The role of bevacizumab in the treatment of non-small cell lung cancer : Current indications and future developments. / Gridelli, Cesare; Maione, Paolo; Rossi, Antonio; De Marinis, Filippo.

In: The oncologist, Vol. 12, No. 10, 10.2007, p. 1183-1193.

Research output: Contribution to journalArticle

@article{cb203df913124977bf7420121de634a1,
title = "The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments",
abstract = "The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease, and despite the improvement in efficacy and safety outcomes with platinum-based chemotherapy, this standard cytotoxic approach has reached a therapeutic plateau, with the prognosis for this clinical condition remaining poor. Advances in the knowledge of tumor biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. Bevacizumab, an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, is the antiangiogenic agent at the most advanced stage of development in the treatment of solid tumors and also in NSCLC treatment. Bevacizumab, combined with platinum-based chemotherapy, has been demonstrated to improve efficacy outcomes over chemotherapy alone in the treatment of nonsquamous advanced NSCLC in two phase III randomized trials. These represent the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment will include the combination of this agent with other targeted therapies in advanced disease (especially with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor) and the integration of this agent into combined modality approaches for the treatment of early-stage and locally advanced disease.",
keywords = "Angiogenesis, Bevacizumab, NSCLC, Targeted therapy",
author = "Cesare Gridelli and Paolo Maione and Antonio Rossi and {De Marinis}, Filippo",
year = "2007",
month = "10",
doi = "10.1634/theoncologist.12-10-1183",
language = "English",
volume = "12",
pages = "1183--1193",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "10",

}

TY - JOUR

T1 - The role of bevacizumab in the treatment of non-small cell lung cancer

T2 - Current indications and future developments

AU - Gridelli, Cesare

AU - Maione, Paolo

AU - Rossi, Antonio

AU - De Marinis, Filippo

PY - 2007/10

Y1 - 2007/10

N2 - The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease, and despite the improvement in efficacy and safety outcomes with platinum-based chemotherapy, this standard cytotoxic approach has reached a therapeutic plateau, with the prognosis for this clinical condition remaining poor. Advances in the knowledge of tumor biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. Bevacizumab, an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, is the antiangiogenic agent at the most advanced stage of development in the treatment of solid tumors and also in NSCLC treatment. Bevacizumab, combined with platinum-based chemotherapy, has been demonstrated to improve efficacy outcomes over chemotherapy alone in the treatment of nonsquamous advanced NSCLC in two phase III randomized trials. These represent the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment will include the combination of this agent with other targeted therapies in advanced disease (especially with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor) and the integration of this agent into combined modality approaches for the treatment of early-stage and locally advanced disease.

AB - The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease, and despite the improvement in efficacy and safety outcomes with platinum-based chemotherapy, this standard cytotoxic approach has reached a therapeutic plateau, with the prognosis for this clinical condition remaining poor. Advances in the knowledge of tumor biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. Bevacizumab, an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, is the antiangiogenic agent at the most advanced stage of development in the treatment of solid tumors and also in NSCLC treatment. Bevacizumab, combined with platinum-based chemotherapy, has been demonstrated to improve efficacy outcomes over chemotherapy alone in the treatment of nonsquamous advanced NSCLC in two phase III randomized trials. These represent the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment will include the combination of this agent with other targeted therapies in advanced disease (especially with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor) and the integration of this agent into combined modality approaches for the treatment of early-stage and locally advanced disease.

KW - Angiogenesis

KW - Bevacizumab

KW - NSCLC

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=36148992949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148992949&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-10-1183

DO - 10.1634/theoncologist.12-10-1183

M3 - Article

C2 - 17962612

AN - SCOPUS:36148992949

VL - 12

SP - 1183

EP - 1193

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -